Bank Of America Corp Corvus Pharmaceuticals, Inc. Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 392 shares of CRVS stock, worth $2,152. This represents 0.0% of its overall portfolio holdings.

Number of Shares

392

Holding current value

$2,152

% of portfolio

0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.36 - $2.29 $533 - $897	392 New	392 $0
Q4 2023 Feb 14, 2024	SELL	$1.08 - $1.92 $5,461 - $9,709	-5,057 Reduced 99.57%	22 $0
Q2 2023 Aug 14, 2023	BUY	$1.0 - $3.86 $5,079 - $19,604	5,079 New	5,079 $11,000
Q4 2022 Feb 10, 2023	SELL	$0.74 - $1.04 $136 - $191	-184 Reduced 72.44%	70 $0
Q3 2022 Nov 14, 2022	SELL	$0.71 - $1.17 $148 - $244	-209 Reduced 45.14%	254 $0
Q2 2022 Aug 12, 2022	SELL	$0.87 - $2.03 $928 - $2,166	-1,067 Reduced 69.74%	463 $0
Q1 2022 May 16, 2022	SELL	$1.46 - $2.48 $1,165 - $1,979	-798 Reduced 34.28%	1,530 $2,000
Q4 2021 Feb 08, 2022	BUY	$2.34 - $5.31 $5,447 - $12,361	2,328 New	2,328 $6,000
Q3 2021 Nov 15, 2021	SELL	$1.89 - $8.53 $173 - $784	-92 Closed	0 $0
Q2 2021 Sep 13, 2021	BUY	$2.46 - $3.14 $226 - $288	92 New	92 $0

Others Institutions Holding CRVS

# of Institutions

Shares Held

28M

Call Options Held

22.9K

Put Options Held

29.8K

Orbimed Advisors LLC San Diego, CA

6.94M
Shares

$38.1 Million
0.3% of portfolio
Samlyn Capital, LLC New York, NY

6.12M
Shares

$33.6 Million
0.2% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

5.96M
Shares

$32.7 Million
0.03% of portfolio
Adams Street Partners LLC Chicago, IL

3.28M
Shares

$18 Million
2.69% of portfolio
Vanguard Group Inc Valley Forge, PA

1.65M
Shares

$9.06 Million
0.0% of portfolio

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $256M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account